Review of Urate-Lowering Therapeutics: From the Past to the Future
We reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA), and ClinicalTrials.gov. We identified a total of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.925219/full |
| _version_ | 1811339410966315008 |
|---|---|
| author | Christopher Jenkins Christopher Jenkins Jennifer H. Hwang Jennifer H. Hwang Jeffrey B. Kopp Cheryl A. Winkler Sung Kweon Cho Sung Kweon Cho |
| author_facet | Christopher Jenkins Christopher Jenkins Jennifer H. Hwang Jennifer H. Hwang Jeffrey B. Kopp Cheryl A. Winkler Sung Kweon Cho Sung Kweon Cho |
| author_sort | Christopher Jenkins |
| collection | DOAJ |
| description | We reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA), and ClinicalTrials.gov. We identified a total of 36 drugs, including 10 approved drugs, 17 in clinical testing phases, and 9 in preclinical developmental phases. The 26 drugs currently undergoing testing and development include 5 xanthine oxidase inhibitors, 14 uricosurics, 6 recombinant uricases, and one with multiple urate-lowering mechanisms of action. Herein, we reviewed the benefit and risk of each drug summarizing currently available drugs. New trials of uricosuric agents are underway to develop the new indication. New drugs are going on to improve the potency of recombinant uricase and to develop the new route administration of such as oral formulation. This review will provide valuable information on the properties, indications, and limitations of ULTs. |
| first_indexed | 2024-04-13T18:26:14Z |
| format | Article |
| id | doaj.art-04ad5a141790479fa67e845851f7debe |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T18:26:14Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-04ad5a141790479fa67e845851f7debe2022-12-22T02:35:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.925219925219Review of Urate-Lowering Therapeutics: From the Past to the FutureChristopher Jenkins0Christopher Jenkins1Jennifer H. Hwang2Jennifer H. Hwang3Jeffrey B. Kopp4Cheryl A. Winkler5Sung Kweon Cho6Sung Kweon Cho7Department of Internal Medicine, University of Connecticut Health Center, Farmington, CT, United StatesDepartment of Internal Medicine, The Hospital of Central Connecticut, New Britain, CT, United StatesDepartment of Internal Medicine, University of Connecticut Health Center, Farmington, CT, United StatesDepartment of Internal Medicine, The Hospital of Central Connecticut, New Britain, CT, United StatesKidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United StatesBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, United StatesBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, United StatesDepartment of Pharmacology, Ajou University School of Medicine, Suwon, South KoreaWe reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA), and ClinicalTrials.gov. We identified a total of 36 drugs, including 10 approved drugs, 17 in clinical testing phases, and 9 in preclinical developmental phases. The 26 drugs currently undergoing testing and development include 5 xanthine oxidase inhibitors, 14 uricosurics, 6 recombinant uricases, and one with multiple urate-lowering mechanisms of action. Herein, we reviewed the benefit and risk of each drug summarizing currently available drugs. New trials of uricosuric agents are underway to develop the new indication. New drugs are going on to improve the potency of recombinant uricase and to develop the new route administration of such as oral formulation. This review will provide valuable information on the properties, indications, and limitations of ULTs.https://www.frontiersin.org/articles/10.3389/fphar.2022.925219/fulluric acidULTreviewdruggout |
| spellingShingle | Christopher Jenkins Christopher Jenkins Jennifer H. Hwang Jennifer H. Hwang Jeffrey B. Kopp Cheryl A. Winkler Sung Kweon Cho Sung Kweon Cho Review of Urate-Lowering Therapeutics: From the Past to the Future Frontiers in Pharmacology uric acid ULT review drug gout |
| title | Review of Urate-Lowering Therapeutics: From the Past to the Future |
| title_full | Review of Urate-Lowering Therapeutics: From the Past to the Future |
| title_fullStr | Review of Urate-Lowering Therapeutics: From the Past to the Future |
| title_full_unstemmed | Review of Urate-Lowering Therapeutics: From the Past to the Future |
| title_short | Review of Urate-Lowering Therapeutics: From the Past to the Future |
| title_sort | review of urate lowering therapeutics from the past to the future |
| topic | uric acid ULT review drug gout |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.925219/full |
| work_keys_str_mv | AT christopherjenkins reviewofurateloweringtherapeuticsfromthepasttothefuture AT christopherjenkins reviewofurateloweringtherapeuticsfromthepasttothefuture AT jenniferhhwang reviewofurateloweringtherapeuticsfromthepasttothefuture AT jenniferhhwang reviewofurateloweringtherapeuticsfromthepasttothefuture AT jeffreybkopp reviewofurateloweringtherapeuticsfromthepasttothefuture AT cherylawinkler reviewofurateloweringtherapeuticsfromthepasttothefuture AT sungkweoncho reviewofurateloweringtherapeuticsfromthepasttothefuture AT sungkweoncho reviewofurateloweringtherapeuticsfromthepasttothefuture |